GlassScriptPhysician profile
Zaki Moin
NPI 1740262823
$16,135.07
in general payments reported to CMS, 2019-2025
36 companies · $3,043 in 2025
The $3,043 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $1,987 · 2021: $2,066 · 2022: $2,231 · 2023: $2,786 · 2024: $2,083 · 2025: $3,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,637 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,636.94 |
| Education | $275.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,905.55 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,400.09 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,366.02 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,285.79 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,227.14 | 2021-2025 | |
| Bausch Health US, LLC | $940.73 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $872.04 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $730.63 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $693.55 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $674.05 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neos Therapeutics, LP | $490.41 | 2019-2024 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $482.61 | 2019-2022 | |
| Axsome Therapeutics, INC. | $477.49 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $472.38 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $455.70 | 2019-2024 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $362.12 | 2019-2024 | Perseris, Sublocade |
| Noven Therapeutics, LLC | $296.80 | 2020-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $290.23 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $263.67 | 2019-2020 | |
| Tris Pharma INC | $251.29 | 2019-2025 | Dyanavel Xr |
| Eisai INC. | $231.49 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $218.49 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $206.89 | 2022-2025 | Ingrezza |
| Adlon Therapeutics L.P. | $109.25 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $93.03 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $80.42 | 2020-2022 | |
| Shire North American Group INC | $72.50 | 2019 | |
| Almatica Pharma LLC | $50.03 | 2024-2025 | Loreev Xr |
| Livanova USA, INC. | $39.88 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.59 | 2021 | |
| Bioxcel Therapeutics, INC. | $30.19 | 2024 | Igalmi |
| Avanir Pharmaceuticals, INC. | $15.46 | 2019 | |
| Neuronetics, INC. | $14.56 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaki Moin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.